QYNAPSE offers cloud-based quantitative imaging software that unlocks the potential of AI to provide accurate, fast, and reliable analysis for better patient selection and treatment evaluation. They have already launched QyScore® software for automated quantification of imaging markers for clinical routine and clinical trials worldwide and are also launching QyPredict®, an AI prediction technology for better targeted patient selection in clinical trials. Their team is wholly dedicated to bringing the neuroscience community and patients the clearest, most accurate, and reliable predictors and objective measures of devastating CNS disorders such as Alzheimer's disease, multiple sclerosis, and Parkinson’s disease.